Arnold, A.M., Seymour, L., Smylie, M., Ding, K.Y., Ung, Y., Findlay, B., et al. (2007) Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients after Complete or Partial Response to Induction Chemotherapy with or without Radiation Therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. Journal of Clinical Oncology, 25, 4278-4284.
http://dx.doi.org/10.1200/JCO.2007.12.3083

has been cited by the following article:

• TITLE: Missing the Target?—Targeted Therapy in Small Cell Lung Cancer

  AUTHORS: Karin R. Purshouse

  KEYWORDS: Oncology, Small Cell Lung Cancer, Targeted Therapy, Drug Development

  JOURNAL NAME: Advances in Lung Cancer, Vol.3 No.3, August 22, 2014

  ABSTRACT: Small cell lung cancer [SCLC] is a devastating form of cancer, with most patients harbouring extensive disease at diagnosis and survival of less than 5% at five years. Progress in novel therapies has been limited. This specialist review explores current targeted therapy options and potential areas of development.